STOCK TITAN

BioStem Technologies Inc - BSEM STOCK NEWS

Welcome to our dedicated news page for BioStem Technologies (Ticker: BSEM), a resource for investors and traders seeking the latest updates and insights on BioStem Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioStem Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioStem Technologies's position in the market.

Rhea-AI Summary
BioStem Technologies Inc. (OTC: BSEM) CEO, Jason Matuszewski, will present at the 2024 Planet MicroCap Showcase in Vegas. The company focuses on placental derived biologics for advanced wound care. The event aims to discuss the company's growth strategy for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
conferences
-
Rhea-AI Summary
BioStem Technologies Inc. has completed a two-year audit, positioning itself for an uplisting to a senior stock exchange. The successful audit enhances transparency and regulatory compliance, showcasing robust revenue growth in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
none
-
Rhea-AI Summary
BioStem Technologies Inc. CEO, Jason Matuszewski, will present at the LD Micro Invitational Conference to discuss the company's growth in 2023 and future plans for 2024, including the successful launch of Amniowrap2™. The conference will feature presentations from 80 companies with one-on-one meeting opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.65%
Tags
conferences
Rhea-AI Summary
BioStem Technologies Inc. (BSEM) reported exceptional financial results for the fourth quarter and full year 2023, with revenue reaching $11.5 million, a 1,355% year-over-year growth. The successful commercial launch of AmnioWrap2 drove this growth, leading to a gross margin of 95% and an Adjusted EBITDA income of $1.67 million in the fourth quarter. The company also highlighted key operational achievements, including acquisitions, clinical trials initiation, and product portfolio expansion. Despite increased operating expenses, BioStem projects strong growth in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.65%
Tags
none
-
Rhea-AI Summary
BioStem Technologies Inc. (BSEM) will release its fourth quarter 2023 financial results on April 1st, 2024. The company, specializing in regenerative medicine, will host a conference call to discuss the financial results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
conferences earnings
-
Rhea-AI Summary
BioStem Technologies Inc. (OTC: BSEM) reports a significant increase in net revenues for the fourth quarter of 2023, reaching $11.5 million, and for the full year, reaching $16.7 million. The company highlights the successful launch and widespread acceptance of Amniowrap2™, its innovative placental-derived allograft product. BioStem also announces key operational updates, including commercialization agreements and government contract listings. Recent achievements include the appointment of a new Chief Commercial Officer and the establishment of national pricing for AmnioWrap2TM. The company plans to discuss its financial results in a conference call scheduled for March 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.91%
Tags
none
Rhea-AI Summary
BioStem Technologies Inc. (BSEM) appoints Shawn McCarrey as Chief Commercial Officer, bringing a strong track record of success and deep experience in regenerative medicine markets. Mr. McCarrey has a proven history of transforming care standards in diverse fields such as regenerative medicine, wound care, and podiatry, with significant achievements in boosting company growth rates and expanding sales forces.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
BioStem Technologies Inc. (OTC: BSEM) appoints Patrick Daly to its Board of Directors. Daly brings extensive industry experience and relationships in the Biomaterials and MedTech market segments. He has a successful track record in operations, strategy, sales, marketing, fundraising, and partnership-building.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.26%
Tags
management
-
Rhea-AI Summary
BioStem Technologies Inc. (OTC: BSEM) announces that the Center for Medicare Services (CMS) has established national pricing for its product, AmnioWrap2™, in all Medicare Administrative Contractors (MAC) regions, effective Jan 1, 2024. The company exclusively commercializes AmnioWrap2™ through Venture Medical LLC, an innovative solutions provider in the U.S. wound care market. The CEO emphasized the significance of this achievement, highlighting the benefit it brings to Medicare patients across the United States. The President of Venture Medical LLC expressed eagerness to provide more clinical results and support formal clinical studies, expecting broad product adoption throughout the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.43%
Tags
none
Rhea-AI Summary
BioStem Technologies Inc. (OTC:BSEM) appoints Mr. Thomas J. Dugan as Chairman of the Board. Mr. Dugan brings extensive experience in wound care and surgical fields, having transformed businesses and established new market opportunities. BioStem CEO, Jason Matuszewski, looks forward to benefiting from Mr. Dugan's leadership and industry experience to optimize value for shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.72%
Tags
management
BioStem Technologies Inc

OTC:BSEM

BSEM Rankings

BSEM Stock Data

123.93M
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
Pompano Beach